Table 1 Patient characteristics and outcomes
From: Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
No | Adjuvant TMZ cycles | mTMZ cycles | Histology | KPS score | Metronomic dosage (mg/m2/d) | Diagnosis to first recurrence (months) | Progression free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|---|---|
1 | 1 | 2 | Glioblastoma | 70 | 50 | 2.9 | 3.1 | 71.0 |
2 | 0 | 0 | Glioblastoma | 90 | 25 | 2.4 | N/A | 11.0 |
3 | 1 | 2 | Small cell anaplastic astrocytoma | 70 | 25 | 2.7 | 7.1 | 7.1 |
4 | 20 | 1 | Glioblastoma | 70 | 25 | 23.3 | 1.5 | 9.7 |
5 | 2 | 6 | Glioblastoma | 70 | 50 | 5.8 | 9.9 | 12.7 |
6 | 0 | 19 | Anaplastic ogliodendroglioma | 90 | 25 | 128.6 | >107 | Alive |
7 | 13 | 1 | Glioblastoma | 70 | 50 | 18.1 | 1.9 | 12.6 |
8 | 1 | 5 | Glioblastoma | 60 | 50 | 3.6 | 11.4 | 14.4 |
9 | 0 | 8 | Anaplastic glioma | 70 | 50 | 120.0 | 22.9 | 33.7 |